Industry Leaders Cornwall and Durall Join RTI Surgical

RTI Surgical Holdings, Inc. has announced the hiring of Scott Durall and Bryan Cornwall, Ph.D. to the senior leadership team. Durall has been appointed Chief Commercial Officer, and Cornwall will become the Executive Vice President, Research and Clinical Affairs.

Durall has over three decades of medical device commercial and sales experience. He comes most recently from Earlens Corporation, and previously NuVasive, Inc. as Executive Vice President, Strategic Sales and Operations. His experience also includes sales roles at Boston Scientific and United States Surgical Corporation.

Cornwall is a professional engineer, and was most recently an associate professor at the University of San Diego where he specialized in orthopedic biomechanics. He previously held the role of President for the NuVasive Spine Foundation, a non-profit associated with the spine device company. As a well-rounded individual, Cornwall also developed a folding, full-sized guitar and has run over 20 marathons including at least one on each of the seven continents.

RTI, which expects to close the sale of its OEM business to Montagu Private Equity, LLP by August 31, 2020, is transforming into a pure-play supplier of spinal implant products. The filling of these senior roles at the company follow the December 2019 appointment of Terry Rich as president, Global Spine, who said of the appointments, “Adding two proven and well-respected leaders like Scott and Bryan to RTI strengthens our world-class spine team and gives us the know-how to enhance our position as a top-ten industry player.”

Rich added, “Having previously worked with both Scott and Bryan, I know firsthand they have what it takes for us to accelerate innovation, advance patient care and improve outcomes. I look forward to the positive and lasting impact they will have on all our stakeholders as we prepare to go all in on spine.”

Finally, RTI President and CEO Camille Farhat described his thoughts on the future of RTI, “We are now moving to the next phase of our journey as we prepare to become a global, pure-play spine company. As we do, I am confident we will remain a leading partner of choice for independent surgeons and distributors with our high-growth product platforms, our clinically differentiated innovation, our channel effectiveness, and now our high-caliber leadership team. Today, we have solidified the foundational elements to enable our exciting future in spine.”